ATS 2018 International Conference

Effect of Mepolizumab (100 mg Subcutaneous) on Exacerbation Rate in Patients with Severe Eosinophilic Asthma by Omalizumab Eligibility (US Criteria), and Immunoglobulin E and Eosinophilic Subgroups [Board No. P920]

Location: Board no. P920

Session Type: Thematic Poster Session

Sunday

May

11:15 AM

1:00 PM

Speaker(s)/Author(s)

Marc Humbert

MD, PhD
Assistance Publique-Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Sud;Assistance-Publique–Hôpitaux de Paris, Service de Pneumologie, Hôpital Bicêtre, Université Paris-Su

Frank C. Albers

MD, PhD
GlaxoSmithKline;GSK

Mark C. Liu

MD
Johns Hopkins Asthma & Allergy Center

Eric Speir. Bradford

MD
GlaxoSmithKline;GSK

Daniel J. Bratton

PhD
GSK

Soichiro Hozawa

M.D., Ph.D.
Hiroshima Allergy & Respiratory Clinic;Hiroshima Allergy and Respiratory Clinic

Steven W. Yancey

MBA, MS
GlaxoSmithKline;GSK

View Abstract

Effect of Mepolizumab (100 mg Subcutaneous) on Exacerbation Rate in Patients with Severe Eosinophilic Asthma by Omalizumab Eligibility (US Criteria), and Immunoglobulin E and Eosinophilic Subgroups

Parent Sessions

A34 - ASTHMA CLINICAL STUDIES I
05-20-2018 9:15 AM - 4:15 PM

Event